Table of Contents
Overview
New York, NY – June 19, 2025 – Global Breast imaging technologies Market size is expected to be worth around US$ 13.6 billion by 2034 from US$ 5.9 billion in 2024, growing at a CAGR of 8.7% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 42.1% share with a revenue of US$ 2.5 Billion.
The global breast imaging technologies market is witnessing steady growth due to increasing awareness of early breast cancer diagnosis and advancements in imaging systems. These technologies include mammography, breast ultrasound, breast MRI, tomosynthesis, and molecular breast imaging (MBI), each offering distinct advantages for early detection and treatment planning.
In 2024, breast cancer remains the most commonly diagnosed cancer among women worldwide, accounting for approximately 2.3 million new cases annually, as per the World Health Organization (WHO). This high incidence rate is driving the adoption of breast imaging systems in hospitals, diagnostic centers, and oncology clinics. Mammography continues to lead as the gold standard, with digital breast tomosynthesis showing enhanced lesion detection rates, especially in dense breast tissues.
Innovations such as contrast-enhanced mammography and AI-assisted interpretation tools are improving diagnostic accuracy and workflow efficiency. Furthermore, supportive government programs and national screening campaigns are accelerating the deployment of advanced imaging infrastructure, particularly in developed countries.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continue to approve next-generation imaging systems, ensuring regulatory compliance and safety. As healthcare providers focus on precision diagnostics and population screening, the demand for reliable, non-invasive imaging tools is expected to increase, supporting sustained market expansion through 2030.
Key Takeaways
- In 2024, the global breast imaging technologies market was valued at USD 5.9 billion and is projected to reach USD 13.6 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.
- Based on technology, the market is segmented into ionizing and non-ionizing imaging modalities. Among these, ionizing technologies dominated the market in 2023, accounting for 66.5% of the total market share, driven by the widespread use of mammography and tomosynthesis systems.
- In terms of end use, the market is categorized into hospitals, diagnostic imaging centers, and breast care centers. Of these, hospitals held the largest share in 2023, contributing 47.1% to the global revenue, owing to high patient inflow and advanced infrastructure for breast cancer screening and diagnostics.
- Regionally, North America led the market in 2023, capturing a 42.1% share, supported by government-backed screening programs, the presence of major medical technology providers, and growing awareness of early detection practices.
Segmentation Analysis
- Technology Analysis: The ionizing segment accounted for 66.5% of the market share due to its proven accuracy in early cancer detection. Technologies like digital mammography and tomosynthesis are widely used for their high-resolution imaging capabilities. Ongoing innovations to minimize radiation exposure while preserving image quality are expected to boost adoption. Supportive reimbursement policies and public screening programs further encourage utilization. Integration with AI tools is also enhancing diagnostic outcomes, making ionizing modalities the dominant choice across hospitals and imaging centers.
- End-User Analysis: Hospitals secured a 47.1% market share due to robust investments in diagnostic infrastructure and a high volume of patients seeking breast imaging services. These facilities offer integrated care from screening to treatment making them the preferred setting for complex procedures. Skilled radiologists, multidisciplinary teams, and access to cutting-edge technologies such as digital mammography drive hospital dominance. Government-supported cancer screening programs and favorable insurance reimbursements are expected to further strengthen hospital-based imaging, supporting sustained demand in this segment.
Market Segments
Technology
- Ionizing
- Positron Emission Tomography & Computed Tomography
- Positron Emission Mammography
- MBI/BSGI
- Full-field Digital Mammography
- Electric Impedance Tomography
- Cone-Beam Computed Tomography
- Analog Mammography
- 3D Breast Tomosynthesis
- Non Ionizing
- Ultrasound
- Thermography
- Optical Imaging
- MRI
- Automated Whole-breast Ultrasound
End-use
- Hospitals
- Diagnostic Imaging Centers
- Breast Care Centers
Regional Analysis
North America held the largest share of the global breast imaging technologies market in 2023, accounting for 42.1% of total revenue. This dominance is attributed to the widespread implementation of screening mammography programs and the integration of advanced technologies such as artificial intelligence (AI). AI enhances diagnostic accuracy by analyzing 3D mammographic images and assisting radiologists in identifying early-stage malignancies.
The American Cancer Society continues to report a high number of breast cancer cases annually, underscoring the importance of routine screening. In 2024, the U.S. Preventive Services Task Force (USPSTF) updated its guidelines to recommend biennial screenings beginning at age 40, which is expected to further accelerate adoption.
Meanwhile, the Asia Pacific region is projected to register the highest CAGR over the forecast period. According to GLOBOCAN, the region reported approximately 985,400 new breast cancer cases in 2022, creating an urgent demand for enhanced screening systems.
Government-led awareness campaigns, infrastructural improvements, and international collaborations such as the Asia-Pacific Women’s Cancer Coalition are promoting early detection and expanding access to digital imaging technologies. The World Health Organization’s Global Breast Cancer Initiative is also guiding policy enhancements, collectively driving robust market growth across Asia Pacific.
Emerging Trends
- Three-Dimensional X-Ray Imaging: Digital Breast Tomosynthesis (DBT) and Dedicated Breast CT (BCT) are being adopted to overcome the problem of overlapping tissue in standard mammograms. DBT creates limited “slices” through the breast, while BCT provides full 3D images without compression. These advances can reveal small lesions hidden in dense tissue, improving early cancer detection.
- Photon-Counting Detectors: New X-ray detectors that count individual photons enable better image contrast and lower X-ray doses. By distinguishing photon energies, these systems can enhance tumor visibility and may permit dose reductions of up to 10 % while keeping image clarity high.
- Functional Optical Imaging: Techniques such as diffuse optical imaging and near-infrared spectroscopy are under development to measure blood flow and oxygen levels in breast tissue. These methods can highlight areas of increased vascular activity—often associated with tumors—providing functional information beyond structural images.
- Ultrasound Elastography: Elastography maps the stiffness of breast tissue by analyzing how sound waves travel through it. Since tumors are often stiffer than normal tissue, elastography can help distinguish benign from malignant lesions. This technique is progressing toward routine clinical evaluation for women with inconclusive mammograms.
- AI-Assisted Detection for 3D Images: Computer-aided detection (CAD) software has been cleared by the FDA for use with digital breast tomosynthesis exams. For example, a software device approved in November 2020 analyzes each tomosynthesis view, outlines suspicious areas, and assigns confidence scores to aid radiologists in identifying lesions more efficiently.
Use Cases
- Routine Population Screening: In 2022, 76.5 % of U.S. women aged 50–74 reported having had a screening mammogram in the past two years. The integration of 3D tomosynthesis into these programs aims to further boost early detection rates and reduce recalls.
- Supplemental Screening in Dense Breasts: A review of 41 studies encompassing 228,508 women showed that adding technologies such as tomosynthesis or handheld ultrasound to standard mammography significantly improved cancer detection rates in women with dense breast tissue.
- Diagnostic Mammography in Clinical Practice: In 2019, physician office visits where mammograms were ordered or performed totaled 27.3 million. Advanced imaging tools such as contrast-enhanced mammography are increasingly used during these visits to clarify ambiguous findings.
- Government-Funded Screening Programs: Under the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), about 5.3 % of U.S. women aged 40–64 were eligible for free screening services in 2016–2017, and the program served 15 % of those eligible, highlighting the role of targeted outreach in underserved populations.
- Guideline-Driven MRI Use for High-Risk Women: The U.S. Preventive Services Task Force recommends women aged 40–74 at average risk receive mammography every two years, with supplemental MRI for those at higher than average risk. These combined protocols aim to balance early detection with minimization of unnecessary procedures.
Conclusion
The global breast imaging technologies market is experiencing robust growth driven by rising breast cancer incidence, technological advancements, and expanding screening programs. Ionizing modalities, particularly digital mammography and tomosynthesis, continue to dominate due to their diagnostic precision. Hospitals lead in adoption, supported by government-backed reimbursement and screening initiatives.
North America holds the largest market share, while Asia Pacific is projected to grow at the fastest pace due to increasing awareness and healthcare investments. Emerging trends such as AI integration, 3D imaging, and functional modalities are enhancing diagnostic outcomes, positioning breast imaging technologies as essential tools in modern cancer detection and management.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
